MADISON, Wis. - Gentel Biosciences hires Dan Clutter, Ph.D., as Vice President of Commercial Development.
Dr. Clutter has responsibility for Sales, Marketing and Product Commercialization. Prior to joining Gentel, Dr. Clutter has been in Sales, Marketing and/or Business Development for PerkinElmer, Invitrogen, Roche, Celera, PanVera, Asterand and NimbleGen.
Dr. Clutter said, “Gentel is well positioned to be a leader in high throughput biomarker discovery and screening. Our expertise in quantitative multiplexed protein assays - coupled with some amazing new profiling applications - gives us the ability to screen for biomarkers that no one could screen for previously.” He added, “I started out my career as a protein biochemist and moved into the genomics arena in time to be a part of new ‘science changing’ technologies such as PCR, shotgun sequencing of the human and mouse genomes, and high resolution tiling microarrays. It’s time for proteomics to have a similar leap in technology.”
“Dan brings Gentel a wealth of scientific knowledge and expertise in product commercialization that directly relates to the pending launch of several new biomarker products and a low cost multiplex scanner. We are very pleased to have Dan as a member of our executive team at Gentel,” commented Gentel President and CEO, Alex Vodenlich.
Gentel Biosciences provides products and services that enable novel approaches to high throughput biomarker discovery and screening. Gentel’s mission is to work closely with its customers to provide the best solution to their quantitative or qualitative assay needs. These solutions leverage Gentel’s expertise, including a proprietary array platform, custom protein arrays, assay development services, sample processing services and colorimetric or fluorescent detection.
